Irbetens

Irbesartan, the active ingredient in Irbetens, is a Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is employed to treat high blood pressure, manage heart failure, and protect kidney function in patients with diabetic nephropathy.

GNH USA supplies Irbetens as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. All shipments are accompanied by full documentation and batch release certificates.

Irbesartan is used to manage conditions related to the renin‑angiotensin system, primarily cardiovascular and renal disorders. - Hypertension: lowers systemic blood pressure and reduces the risk of stroke, myocardial infarction, and other cardiovascular events in adult patients. - Heart failure: improves cardiac output, decreases hospitalization rates, and alleviates symptoms by reducing afterload and preventing adverse ventricular remodeling. - Diabetic nephropathy: slows progression of kidney damage, lowers intraglomerular pressure, and reduces proteinuria, helping preserve renal function in patients with type 2 diabetes. - Proteinuria: reduces urinary protein excretion, contributing to renal protection in patients with hypertension‑related kidney disease.

Irbesartan may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Fatigue: feeling unusually tired or weak. - Hyperkalemia: elevated blood potassium levels.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or airway requiring immediate medical attention. - Acute renal failure: sudden decline in kidney function, indicated by rising creatinine. - Hepatic injury: elevated liver enzymes or signs of hepatitis. - Severe hypotension: marked drop in blood pressure causing faintness or shock.

When prescribing Irbesartan, clinicians should observe several precautionary measures to ensure patient safety. - Monitor blood pressure: adjust dose if target not achieved. - Assess renal function: check serum creatinine and eGFR before and during therapy. - Check electrolytes: especially potassium levels to avoid hyperkalemia. - Use caution in hepatic impairment: dose may need adjustment in severe liver disease. - Avoid in pregnancy: drug category unknown; discontinue if pregnancy is detected. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Irbesartan can interact with other medicines, and some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use may increase risk of renal impairment. - Dual blockade with ACE inhibitors or other ARBs: may cause excessive hypotension and hyperkalemia. - Potassium‑sparing diuretics: increase risk of dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - Lithium: may raise lithium levels, requiring serum monitoring. - NSAIDs: can reduce antihypertensive effect and affect renal function. - Cyclosporine: may increase serum irbesartan concentrations.